You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Radiation retinopathy treated successfully with aflibercept
  1. Pakinee Pooprasert1,
  2. Tafadzwa Young-Zvandasara2,
  3. Ayad Al-bermani2
  1. 1Ophthalmology Department, Cardiff University, Cardiff, UK
  2. 2Ophthalmology Department, University Hospital Wales, Cardiff, UK
  1. Correspondence to Pakinee Pooprasert, pooprasertp{at}cardiff.ac.uk

Summary

Aflibercept (aflibercept) is a novel anti-vascular endothelial growth factor drug indicated for wet age-related macular degeneration and macular oedema secondary to retinal vein occlusion and diabetic macular oedema. While only newly introduced on the market, it is growing in popularity and over 5.5 million doses have been prescribed worldwide. Due to its versatile mechanism, it is indicated for numerous eye pathologies, and in particular, has been adapted to treat various types of retinopathy. To our knowledge, this is the first case report of solely using aflibercept to treat cystoid macular oedema in radiation retinopathy.

  • ophthalmology
  • retina

https://doi.org/10.1136/bcr-2017-220744

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors TY-Z and AA-b were responsible for collecting patient information and results while PP was responsible for writing the case report.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.